scholarly journals O5-6.2 Surgical treatment of elderly breast cancer patients with distant metastases at diagnosis

2011 ◽  
Vol 65 (Suppl 1) ◽  
pp. A56-A57
Author(s):  
E. Bastiaannet ◽  
S. van de Velde ◽  
W. van de Water ◽  
M. Ernst ◽  
A. Voogd ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Cancer Patients ◽  
Distant Metastases ◽  
Breast Cancer Patients

14. Surgical treatment of elderly breast cancer patients with distant metastases at diagnosis

2012 ◽  
Vol 38 (9) ◽  
pp. 736
Author(s):  
M. Kinderlen ◽  
W. Van de Water ◽  
S. Van der Velde ◽  
E. Bastiaannet ◽  
M.F. Ernst ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Cancer Patients ◽  
Distant Metastases ◽  
Breast Cancer Patients

CHANGES IN THE NIPPLE-AREOLA COMPLEX IN PATIENTS WITH BREAST CANCER

2017 ◽  
Vol 63 (4) ◽  
pp. 593-597
Author(s):  
Aziz Zikiryakhodzhaev ◽  
Nadezhda Volchenko ◽  
Erik Saribekyan ◽  
Yelena Rasskazova
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Cancer Patients ◽  
Molecular Subtypes ◽  
Breast Cancer Patients ◽  
Nipple Areola Complex ◽  
Histological Types ◽  
Areola Complex

The article presents data about the lesion of the nipple-areola complex in breast cancer. In 2015-2016 surgical treatment was performed in 101 breast cancer patients, different in size but with the mandatory removal of the nipple-areola complex. There are analyzed the dependence of the lesion of the nipple-areola complex from histological types of breast cancer, molecular subtypes, multicentricity, the location of tumor in the breast. The most significant criterion was the dependence of the lesion of the nipple-areola complex from the distance between tumor node and the nipple.

Omission of Surgical Treatment and Survival of Elderly Breast Cancer Patients

2013 ◽  
Vol 4 ◽  
pp. S17
Author(s):  
N.A. De Glas ◽  
J. Jonker ◽  
E. Bastiaannet ◽  
A.J.M. de Craen ◽  
C.J.H. van de Velde ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Cancer Patients ◽  
Breast Cancer Patients

scholarly journals Platelet-Rich Plasma (PRP) in Breast Cancer Patients: An Application Analysis of 163 Sentinel Lymph Node Biopsies

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
C. Eichler ◽  
C. Baucks ◽  
J. Üner ◽  
C. Pahmeyer ◽  
D. Ratiu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sentinel Node ◽  
Cancer Patients ◽  
Sentinel Node Biopsy ◽  
Platelet Rich Plasma ◽  
Distant Metastases ◽  
Complication Rates ◽  
Breast Cancer Patients ◽  
Node Biopsy

Introduction. Literature shows platelet-rich plasma (PRP) to improve overall outcomes in orthopedics, dermatology, ophthalmology, gynecology, and plastic surgery. Data on oncological patients is very limited. Only one publication is available on PRP in breast cancer patients. This work evaluated PRP in sentinel node biopsy procedures for breast cancer patients in terms of complication rates and oncological short-term follow-up. Methods. The evaluated PRP was ACP®, i.e., autologous conditioned plasma by Arthrex®. Between 2015 and 2018, 163 patients were offered to receive an ACP®/PRP injection in their lymph node biopsy site. Recruitment resulted in an approximate one-to-one ratio for analysis. Endpoints were major (revision) and minor (seroma, hematoma, and infection) complications rates as well as distant metastases, local recurrence, and overall survival. Median follow-up was 30 months. Results. Complication rates and oncological follow-up showed PRP to be applicable to use in a sentinel node biopsy scenario in breast cancer patients. There were 0 revisions in the ACP®/PRP group and 1.2% revisions in the control group (not significant). Oncological follow-up showed zero (0) distant metastases and local recurrences as well as a 100% 30-month overall survival. Conclusions. This is the first analysis of ACP®/PRP used in breast cancer patients in a sentinel node biopsy setting worldwide. PRP does not seem to increase rates of local recurrence within this 30-month follow-up time frame. Also, trend towards decreasing complication rates could be shown.

Circulating Ca 15.3 Levels in Breast Cancer. Our Present Experience

1986 ◽  
Vol 1 (2) ◽  
pp. 89-92 ◽  
Author(s):  
Ramon Colomer ◽  
Alvaro Ruibal ◽  
Matilde Navarro ◽  
Gloria Encabo ◽  
Luis Alfonso Sole ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Objective Response ◽  
Stage Iv ◽  
Distant Metastases ◽  
Response To Therapy ◽  
Breast Cancer Patients ◽  
Benign Diseases ◽  
Ca 15.3 ◽  
Stage Iv Breast Cancer

CA 15.3 is an antigen expressed by human breast carcinoma cells, and defined by two monoclonal antibodies, 115D8 and DF3. We used IRMA to determine the circulating serum levels of CA 15.3 in 1178 subjects with breast cancer, non-breast malignancies, benign diseases and controls. A threshold level of 40 U/ml was established with 140 healthy controls and 650 patients with benign diseases (respectively 0% subjects and 1.5% patients had abnormal antigen levels). Elevated CA 15.3 was found in 12 of 184 patients with malignancies different from breast cancer (6.5%), either epithelial carcinomas with distant metastases, mainly in the liver, or primary liver tumors. Breast cancer patients (n=204) were analysed by prior therapy, UICC stage and WHO response to therapy. Eight of 134 (5.9%) patients with stage II or III breast cancer at presentation and no evidence of disease (NED) had elevated CA 15.3. All of 22 patients with stage IV breast cancer not responding to therapy (SD and PD) had antigen levels > 40 U/ml, as did 10 of 34 (29.4%) stage IV patients in objective response (CR+PR). Three of 14 pretreatment patients had abnormal marker levels, and they later proved to have distant metastases. Serum CA 15.3 values were statistically different (p < 0.01) in NED (20.6 ± 11.2 U/ml), CR+PR (33.5 ± 24.0 U/ml), stable disease (98.8 ± 50.4 U/ml) and progressive disease (> 200 U/ml) breast cancer patients. Our results suggest that circulating CA 15.3 antigen levels agree with the stage of breast cancer and with the response to therapy.

Sign in / Sign up

Export Citation Format

Share Document